← Latest news 
Bayer to buy Perfuse Therapeutics in up to 2.45 billion deal
Business
Published on 6 May 2026
A glaucoma drug in trials could be the prize
Bayer plans to acquire Perfuse Therapeutics in a deal worth up to $2.45 billion, aiming to strengthen its eye care pipeline. The purchase includes PER-001, currently in clinical trials and targeting glaucoma and diabetic retinopathy, two major causes of vision loss. The move signals Bayer’s push to expand treatment options through late-stage development.
- Bayer will buy Perfuse Therapeutics for up to $2.45 billion
- Deal targets growth in Bayer’s eye care treatments
- PER-001 is in clinical trials for glaucoma and diabetic retinopathy
- Acquisition could accelerate new therapies for vision-threatening diseases
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times